Trials / Completed
CompletedNCT00190723
A Study of LY317615 in Patients With Brain Tumors
A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzastaurin |
Timeline
- Start date
- 2002-10-01
- Completion
- 2006-12-01
- First posted
- 2005-09-19
- Last updated
- 2007-01-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00190723. Inclusion in this directory is not an endorsement.